Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds
Publishing timestamp: 2023-04-27 13:07:14
Summary
Eli Lilly's weight loss drug tirzepatide has shown promising results in clinical trials, with patients losing up to 34 pounds or 16% of their body weight. The company plans to apply for FDA approval in the coming weeks and expects regulatory action later this year. The drug was previously approved for Type 2 diabetes but not for weight loss. The weight loss industry has seen increased demand, but some experts criticize the use of drugs as potentially harmful. Tirzepatide works by mimicking two hormones in the gut that signal fullness and suppress appetite.
Sentiment: POSITIVE
Keywords: pandemics, epidemics, biotech and pharmaceuticals, politics, health care industry, breaking news: business, disease outbreaks, coronavirus, united states, business, business news, u.s. economy, biotechnology, science, novo nordisk a/s, eli lilly and co,
Source: https://www.cnbc.com/2023/04/27/eli-lilly-weight-loss-drug-tirzepatide-data-released.html